The BEACON trial randomized patients with BRAF V600E-mutant metastatic colorectal cancer who had disease progression after 1–2 previous lines of therapy to receive encorafenib, binimetinib, and cetuximab (triplet therapy group); encorafenib and cetuximab (doublet therapy group); or the investigators’ choice of either cetuximab and irinotecan or cetuximab and FOLFIRI [17]. Here, BRAF is linked to metastatic colorectal cancer.